TUMOR IMMUNOLOGY.pdf

More documents

Recommendations

Info

Local and regional IL-2 administration in cancer patients - selected examples from the early trials Interleukin-2 Dose Tumour Response (%) Reference (units/patient) ti t) Complete/partial ti l gibbon lymphoid 1.5 x 10-2 – 4.0 x 10-3 urinary bladder carcinomas 30/ 30 Pizza (1984) human recombinant 1.0 x 10-4 – 2.8 x 10-4 lung carcinomas 0/ 82 Yasumoto (1987) human recombinant 8.0 x 10-2 – 5.4 x 10-3 malignant gliomas 13/ 13 Yoshida (1988) human lymphoid 2.0 x 10-3 squamous cell carcinomas 29/ 29 Forni (1988) human lymphoid 2.0 x 10-3 squamous cell carcinomas 30/ 30 Cortesina (1988) human lymphoid continuous perfusion urinary bladder carcinomas 20/ n.v. Huland and Huland 1.5 x 10-6/week (1989) n.v., not verified because of incomplete transurethral resection
Adoptive immunotherapy • Stimulating immune cells by exposing them to tumour cells or antigens in the laboratory and then injecting expanded populations of the treated cells into patients. • Patient is both donor and recipient.
Page 1 and 2:
Cancer Immunology and Immunotherapy
Page 3 and 4:
Definitions of Cancer • Cancer co
Page 5 and 6:
Neoplastic Transformation -- Carcin
Page 7 and 8:
Current strategies to combat cancer
Page 9 and 10:
Cancer Immunology and Immunotherapy
Page 11:
Cancer Immunosurveilance • The hy
Page 14: Army of the host to fight cancers A
Page 17 and 18: Helper T cells CD4+ T cells: reacti
Page 19 and 20: Other cells NK cells: after activat
Page 21 and 22: Antibody - produced by B cells •
Page 23 and 24: How does cancer Single cancer cell
Page 25 and 26: Mechanisms of cancer escape from th
Page 27 and 28: (1) Loss/down-regulation of HLA cla
Page 29 and 30: Tumor Antigens • Altered self: K-
Page 31 and 32: T cell Activation T cell No Activat
Page 33 and 34: (4) Alterations in cell death recep
Page 36 and 37: (6) Induction of Immunosuppressive
Page 38 and 39: Potential sources for regulatory T
Page 40 and 41: (7) Production of other suppressive
Page 42 and 43: 1. Weapons from the tumors 2. Defec
Page 44 and 45: Immune defects in T cells in cancer
Page 46 and 47: Malfunction of dendritic cell syste
Page 48: Summary How do tumors progress
Page 51 and 52: The fortune of tumor cells depends
Page 53 and 54: Cancer Immunology/Immunotherapy •
Page 55 and 56: Immunotherapy --- Reverse the imbal
Page 57 and 58: Strategies to block the suppressive
Page 59 and 60: History: Non-specific approach •
Page 61 and 62: Examples
Page 63: Event Discovery of IL-2 Cytokine th
Page 67 and 68: Adoptive immunotherapy The Journal
Page 69 and 70: Antitumor Vaccines
Page 71 and 72: Approaches to antitumor vaccination
Page 73 and 74: Combinational Therapy -- a three-st
Page 76 and 77: The immune system can be harnessed
Page 78 and 79: Potential mechanisms for synergy di
Page 80 and 81: Novel co-stimulatory molecule- B7H3
Page 82 and 83: Combinational therapy led to eradic
Page 84 and 85: Treatment of single tumor eradicate
Page 86 and 87: Background - mini review Introducti
show all

TUMOR IMMUNOLOGY.pdf

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?